Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is ...

The Huntington disease (HD) Digital Motor Score (HDDMS), which is derived from smartphone sensor-based motor tests included ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information ...

Rheumatic fever is a serious inflammatory condition that can develop after an untreated strep throat infection. It mainly ...

Patients with Huntington's often receive anti-dopaminergic medications, such as neuroleptic medications or vesicular monoamine transporter type 2 (VMAT2) inhibitors, to manage chorea and some ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT ®-HD study showcasing significant improvements in chorea across body regions ...

Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 years. Classification criteria identified fewer than 50% of patients as having ...

The KINECT-HD2 study is an open-label clinical trial assessing the long-term safety and efficacy of INGREZZA, a vesicular monoamine transporter 2 (VMAT2) inhibitor, for adults with chorea ...

Robust and sustained improvements in chorea associated with Huntington's disease were observed through Week 104 in patients, irrespective of concomitant antipsychotic therapy use. These results ...

Ingrezza (in-GREH-zah) was approved in 2017 as the first medicine to help control movement in people with tardive dyskinesia and was approved for use in people with chorea caused by Huntington’s ...

All gave the impression of restlessness observed in patients with Sydenham's chorea. None had speech defects beyond the somewhat careless pronunciation characteristic of their environment.